Ignite Creation Date:
2025-12-24 @ 9:22 PM
Ignite Modification Date:
2025-12-25 @ 7:09 PM
Study NCT ID:
NCT01038804
Status:
COMPLETED
Last Update Posted:
2013-09-18
First Post:
2009-12-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Sponsor:
Astellas Pharma Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-12
Start Date Type:
None
Primary Completion Date:
2012-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-06
Completion Date Type:
ACTUAL
First Submit Date:
2009-12-22
First Submit QC Date:
None
Study First Post Date:
2009-12-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2013-07-15
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2013-09-12
Last Update Post Date:
2013-09-18
Last Update Post Date Type:
ESTIMATED